AMPHASTAR PHARMACEUTICALS IN - NOTE 2.000% 3/1

CUSIP: 03209RAB9

Q4 2025 13F Holders as of 31 Dec 2025

Type / Class
Debt / NOTE 2.000% 3/1
Market price (% of par)
92.46%
Total 13F principal
$337,272,006
Principal change
+$38,613,800
Total reported market value
$312,110,942
Number of holders
41
Value change
+$35,882,119
Number of buys
11
Number of sells
16

Quarterly Holders Quick Answers

What is CUSIP 03209RAB9?
CUSIP 03209RAB9 identifies 03209RAB9 - AMPHASTAR PHARMACEUTICALS IN - NOTE 2.000% 3/1 in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of AMPHASTAR PHARMACEUTICALS IN - NOTE 2.000% 3/1 as of Q4 2025

As of 31 Dec 2025, AMPHASTAR PHARMACEUTICALS IN - NOTE 2.000% 3/1 was held by 41 institutional bondholders reporting positions in Form 13F filings. These institutions reported holding $337,272,006 in principal (par value) of the bond. The largest 10 bondholders included Linden Advisors LP, OAKTREE CAPITAL MANAGEMENT LP, CAMDEN ASSET MANAGEMENT L P /CA, Context Capital Management, LLC, Wellesley Asset Management, Empyrean Capital Partners, LP, TENOR CAPITAL MANAGEMENT Co., L.P., Calamos Advisors LLC, MORGAN STANLEY, and SILVERBACK ASSET MANAGEMENT LLC. This page lists 41 institutional bondholders reporting positions for the Q4 2025 filing period.
Investor Option Weight % Change % Value $ * Price (% of par) Principal Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.